Amotiv Limited (AOV) - Total Liabilities

Latest as of December 2025: CA$279.03 Million CAD ≈ $201.84 Million USD

Based on the latest financial reports, Amotiv Limited (AOV) has total liabilities worth CA$279.03 Million CAD (≈ $201.84 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AOV net assets growth trend to track the company's year-over-year net asset growth rate.

Amotiv Limited - Total Liabilities Trend (2014–2025)

This chart illustrates how Amotiv Limited's total liabilities have evolved over time, based on quarterly financial data. See Amotiv Limited free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Amotiv Limited Competitors by Total Liabilities

The table below lists competitors of Amotiv Limited ranked by their total liabilities.

Company Country Total Liabilities
Tianjin Keyvia Electric Co Ltd
SHE:300407
China CN¥1.78 Billion
Korea Investment Holdings Co Ltd
KO:071055
Korea ₩135.15 Trillion
Shenzhen TXD Technology Co Ltd
SHE:002845
China CN¥6.72 Billion
Lanzhou Foci Pharmaceutical Co Ltd
SHE:002644
China CN¥678.01 Million
Chengdu Xiling Power Science & Technology Incorporated Co Class A
SHE:300733
China CN¥1.58 Billion
Guangdong Super Telecom
SHG:603322
China CN¥1.91 Billion
Shanghai New World Co Ltd
SHG:600628
China CN¥1.47 Billion
Jenkem Technology Co Ltd
SHG:688356
China CN¥81.71 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Amotiv Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Amotiv Limited (AOV) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.39 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.03 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amotiv Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amotiv Limited (2014–2025)

The table below shows the annual total liabilities of Amotiv Limited from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 CA$279.03 Million
≈ $201.84 Million
+65.41%
2024-12-31 CA$168.69 Million
≈ $122.03 Million
-15.07%
2023-12-31 CA$198.62 Million
≈ $143.68 Million
-13.26%
2022-12-31 CA$228.98 Million
≈ $165.64 Million
+52.78%
2021-12-31 CA$149.87 Million
≈ $108.42 Million
-2.32%
2020-12-31 CA$153.44 Million
≈ $110.99 Million
-60.68%
2019-12-31 CA$390.20 Million
≈ $282.26 Million
+1689.89%
2018-12-31 CA$21.80 Million
≈ $15.77 Million
+47.55%
2017-12-31 CA$14.78 Million
≈ $10.69 Million
+33.69%
2016-12-31 CA$11.05 Million
≈ $7.99 Million
+59.57%
2015-12-31 CA$6.93 Million
≈ $5.01 Million
-9.14%
2014-12-31 CA$7.62 Million
≈ $5.51 Million
--

About Amotiv Limited

TO:AOV Canada Drug Manufacturers - Specialty & Generic
Market Cap
$721.61 Million
CA$997.54 Million CAD
Market Cap Rank
#11318 Global
#333 in Canada
Share Price
CA$9.84
Change (1 day)
+0.72%
52-Week Range
CA$5.75 - CA$10.07
All Time High
CA$10.90
About

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more